Jon Napitupulu

Korro Bio has nominated KRRO-121 as its next clinical candidate for the treatment of hyperammonemia in urea cycle disorders...

Hims & Hers posted its best weekly stock gain after announcing a deal with Novo Nordisk, and Wall Street...

Lyell Immunopharma has begun dosing in a first-of-its-kind phase 3 head-to-head randomized trial in second-line large B-cell lymphoma, testing...

Bolt Biotherapeutics reported 2025 results and advanced its first-in-class immune-stimulating antibody conjugate, BDC-4182, into a Phase 1 dose-escalation study...

Vaxart reported a pivotal business update: enrollment is complete in its approximately 5,400-participant phase 2b COVID-19 trial comparing an...

Allogene Therapeutics has set two near-term catalysts that could redefine where and how cell therapy is used: an April...

Corvus Pharmaceuticals reported positive cohort 4 results from its randomized, blinded phase 1 trial of soquelitinib in moderate-to-severe atopic...

ProQR Therapeutics reported year-end 2025 results and a business update centered on advancing its Axiomer RNA editing platform. The...

Gyre Therapeutics is buying Cullgen in an all‑stock deal valued at approximately $300 million, aiming to close in the...

Codexis reported fourth-quarter 2025 revenue of $38.9 million and full-year revenue of $70.4 million, buoyed by a $37.8 million...